Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 6

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 6
---
 $ 
    $ 

  Sales tax receivables
  
    —  
   106 

  Other receivables
  
   20 
   20 

  Total receivables
  
   20 
   126 

  13
  

5. Trade and other payables

  June 30, 2025

  March 31, 2025

   $  
   $  

  Trade
  payables
  
   1,339 
   601 

  Accrued
  research and development expenses
  
   637 
   565 

Employee salaries and benefits
payable

   303 
   661 

  Accrued
  liabilities and payables
  
   36 
   103 

  Total
  trade and other payables
  
   2,315 
   1,930 

   6. Stockholders’ equity

   Preferred Stock
   
   The Company is authorized to issue up to 10,000,000 shares of preferred stock, par value $0.0001 per share. No shares of the Company’s preferred stock are issued or outstanding.  
  
   Common Stock
   
   In connection with the consummation of the Domestication, on October 7, 2024, the Company adopted a Certificate of Incorporation (as amended, the “Charter”) and Bylaws (as amended, the “Bylaws”). The rights of holders of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”) are governed by the Charter, the Bylaws, and the General Corporation Law of the State of Delaware. The Company is authorized to issue up to 100,000,000 shares of Common Stock.
   2025 Private Placement
   
   In February 2025, the Company agreed to offer and sell in a private placement (the “2025 Private Placement”) an aggregate of 3,252,132 shares of Common Stock at a purchase price of $3.395 per share of Common Stock (the “Shares”) and pre-funded warrants (the “2025 Pre-Funded Warrants”) to purchase up to 1,166,160 shares of Common Stock at a purchase price equal to the purchase price per Share less $0.0001 (the “2025 Pre-Funded Warrant Shares”). Each 2025 Pre-Funded Warrant is